Technologies

1. Technical overview

Description and Manufacturing method of Chimeric Mutant Vaccine of Porcine Reproductive and Respiratory Syndrome virus which can be used as Vaccine

two。 The effect of technology

Chimeric virus mutants have low pathogenicity and high safety in pigs

A wide range of defenses

Antibody titers can be obtained even with dead vaccines alone.

Because it reacts quickly to local popular varieties, it has a good defense ability.

The SP part of PRRSV can be replaced and can cope with sudden changes, which is simple and economical.

3. Technical content

Terminology

-PRRSV FL12: inserted NVSL97-7895 mutant into the infectious clone of pBR322 vector. North American PRRSV isolate mainly caused abortion and stillbirth virulent strain in sows.

-PRRSV LMY: is a representative variant in Korea and its pathogenicity is not strong.

-K418: a mutant with a base sequence recorded by SEQ ID NO1

-K418DM: a mutant with a base sequence recorded by SEQ ID NO2

Production of Chimeric Mutants

-SEQ ID NOS:1 to 12160 and 15467 to 19231:PRRSV FL12 sequences

-SEQ ID NOS:12161 to 15466:PRRSV LMY sequence.

The coding regions of GP5 protein were mutated from 13886 to 13888 and 13940 to 13942 to deglycosylation.

K418 produces a chimeric mutant of Porcine Reproductive / Respiratory Syndrome virus with SEQ ID NO:1 nucleotide sequence by combining the ORF (Open Reading frame) 1 region of NVSL 97 / 7895 and the ORF2 to ORF7 region of LMY.

The ORF1 region of NVSL 97 / 7895 mutant and the ORF2 to ORF7 gene of LMY mutant and the mutant PRRSV chimeric mutant of GP5 (heterodimer with one of the glycosylated structural proteins to increase the infection of the virus) were encoded in the combined base sequence.